TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
|Articles|May 1, 2001
Supplements and Featured Publications
- Artherosclerosis: Achieving Optimal Outcomes in Statin Therapy
- Volume 7
- Issue 5 Suppl
Statins--Differences and Similarities
Author(s)Terje Pedersen, MD, PhD, Allan Gaw, MD, PhD
Advertisement
Articles in this issue
over 25 years ago
Participating Facultyover 25 years ago
Introductionover 25 years ago
Threshold Level or Not for Low-Density Lipoprotein Cholesterolover 25 years ago
What Do the Statin Trials Tell Us?over 25 years ago
New Therapies on the Horizonover 25 years ago
A New Statin: A New StandardAdvertisement
Related to this article
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
4
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
5